Comparative Pharmacology
Head-to-head clinical analysis: OXYCODONE 5 APAP 500 versus QOLIANA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXYCODONE 5 APAP 500 versus QOLIANA.
OXYCODONE 5/APAP 500 vs QOLIANA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oxycodone: mu-opioid receptor agonist; Acetaminophen: cyclooxygenase (COX) inhibition, analgesic and antipyretic via central action.
QOLIANA (elagolix) is a nonpeptide, orally active gonadotropin-releasing hormone (GnRH) receptor antagonist that competitively binds to GnRH receptors in the pituitary gland, thereby reducing the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This leads to decreased ovarian production of estrogen and progesterone, resulting in a hypoestrogenic state.
1-2 tablets (oxycodone 5-10 mg/APAP 500-1000 mg) orally every 4-6 hours as needed for pain; maximum APAP dose 4000 mg/day from all sources.
Initiate at 5 mg orally once daily, increase as tolerated to 10 mg once daily. Maximum dose 20 mg once daily.
None Documented
None Documented
Oxycodone: Terminal half-life 3.5-5.6 hours (mean 4.5 h); prolonged in renal/hepatic impairment. Acetaminophen: 2-3 hours.
Terminal elimination half-life is 12 hours (range 10–15 hours) in healthy adults; may extend to 18–24 hours in patients with moderate hepatic impairment (Child-Pugh B).
Renal: Oxycodone ~87% (10% unchanged, 77% as metabolites); Acetaminophen ~85% (2-5% unchanged, rest as glucuronide and sulfate conjugates). Biliary/fecal: Minimal for both.
Renal excretion of unchanged drug accounts for approximately 30% of elimination; biliary/fecal excretion accounts for 60% (including metabolites); 10% is metabolized with negligible pulmonary elimination.
Category D/X
Category C
Opioid Agonist
Opioid Agonist